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Introduction
Atrial ﬁ brillation (AF) is the most common sus-
tained cardiac arrhythmia, aﬀ ecting approximately 
six million Europeans.Th e lifetime risk of developing 
AF is one in four men and women after the age of 
40 years. Th e prevalence of AF increases dramatically 
with age, ranging from 1.5% in individuals aged 50–
59 years to 23.5% in those aged 80–89 years. With an 
ageing population, the prevalence of AF is projected 
to double by 2030.
Stroke is the most devastating complication of AF. 
Atrial ﬁ brillation causes 15–20% of ischemic strokes 
and the overall risk of stroke in patients with non-
valvular AF is about 5% per year. Long-term studies 
have consistently shown that patients with AF have 
a 5-fold increased risk of stroke compared with indi-
viduals without AF. One-third of patients who have 
atrial ﬁ brillation and stroke were not known to have 
atrial ﬁ brillation until their stroke. Stroke in patients 
with AF is nearly twice as likely to be fatal compared 
with non-AF stroke. Th is is due to the development of 
large thrombi in the left atrial appendage which travel 
to the brain causing occlusion of the major intracra-
nial arteries. Th is results in larger infarct volumes and 
more severe strokes. Th e costs of caring for patients 
with stroke associated with AF have been shown to 
be 33% greater for AF-related stroke than for non-AF 
stroke.
Risk stratiﬁ cation for stroke and thrombo-embolism
Th e European Society of Cardiology (ESC) has 
recently extended the CHADS2 scheme by consider-
ing additional stroke risk factors that may inﬂ uence 
a decision whether or not to anticoagulate. Th is risk 
factor-based approach for patients with non-valvular 
AF can also be expressed as an acronym, CHA2DS2-
VASc [congestive heart failure, hypertension, age ≥75 
(doubled), diabetes, stroke (doubled), vascular disease, 
age 65–74, and sex category (female)].Th is scheme is 
based on a point system in which 2 points are assigned 
for a history of stroke or TIA, or age ≥75;and 1 point 
each is assigned for age 65–74 years, a history of hy-
pertension, diabetes, recent cardiac failure, vascular 
disease (myocardial infarction, complex aortic plaque, 
and PAD, including prior revascularization, amputa-
tion due to PAD, or angiographic evidence of PAD, 
etc.), and female sex . 
VKA treatment should be considered for patients 
with AF with ≥1 stroke risk factor(s) provided there 
are no contraindications, especially with careful as-
sessment of the risk–beneﬁ t ratio and an appreciation 
of the patient’s values and preferences. Patients with a 
CHA2DS2-VASc of 1 should be treated with either 
OAC or aspirin 75–325 mg daily (preferred: OAC 
rather than aspirin) and patients with a CHA2DS2-
VASc of 0, either aspirin 75–325 mg daily or no an-
tithrombotic therapy (preferred: no antithrombotic 
therapy rather than aspirin).
Antithrombotic management
Th e magnitude of stroke reduction from aspirin vs. 
placebo (19%) is broadly similar to that seen when as-
pirin is given to vascular disease subjects. Th e eﬃ  cacy 
of warfarin in reducing the risk of stroke in patients 
with AF has been conﬁ rmed by randomized, placebo-
controlled clinical trials. A meta-analysis of 6 major 
studies showed a 64% reduction in the risk of stroke in 
patients with nonrheumatic AF treated with warfarin 
compared with placebo. Survival following a stroke 
was also almost doubled in the patients who received 
anticoagulation treatment compared with those who 
received no treatment. However, 14–44% of patients 
with atrial ﬁ brillation who are at risk of stroke are in-
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eligible for anticoagulation therapy, primarily due to 
the risk of major bleeding. In patients who are eligible, 
the risk of bleeding, the need for frequent INR moni-
toring and dose adjustments, drug interactions, and 
restrictions on diet may explain why warfarin discon-
tinuation rates are as high as 38% per year.
New anticoagulants 
New anticoagulants that selectively block speciﬁ c 
pathways of the coagulation cascade have demonstrat-
ed eﬃ  cacy and safety. Th ese drugs have a fast onset 
and anticoagulation does not need intensive monitor-
ing (Figure).
110 mg than warfarin (2.71 vs. 3.36% per year, p = 
0.003) but similar to warfarin for the higher dose of 
dabigatran (3.11%, p = 0.31). Intracranial bleeding was 
signiﬁ cantly lower for both doses of dabigatran than 
for warfarin (p <0.001 for each dose vs. warfarin). 
Th e ROCKET AF study assessed the eﬃ  cacy and 
safety of rivaroxaban (20 mg once-daily), a novel oral, 
direct Factor Xa inhibitor, compared to warfarin for 
the prevention of stroke. and non-CNS systemic em-
bolism in patients with AF. Rivaroxaban 20 mg was 
noninferior to warfarin in reducing all-cause stroke 
and non-central nervous system (CNS) embolism in 
AF patients, with a similar rate of major bleeding.
Th e AVERROES trial was terminated early be-
cause of demonstrated superiority of apixaban (5 mg 
twice daily) compared to aspirin (81–324 mg daily) 
alone in AF patients unsuited to warfarin, 40% be-
cause of prior problems with the drug. A large-scale 
trial against warfarin in AF (ARISTOTLE) is now 
under way. Other agents in late stage development in 
AF include edoxaban, TAK-442, betrixaban and dar-
exaban.
In Canada, dabigatran has been approved for the 
stroke/AF indication in both the 110-mg and 150-mg 
doses studied in the RE-LY trial, whereas in the US, 
the FDA decided to approve only the 150-mg dose 
and an untested 75-mg dose for patients with se-
vere renal impairment. In April, 2011 the European 
Medicines Agency (EMA) issued a “positive opinion” 
for dabigatran in the setting of atrial ﬁ brillation, for 
prevention of stroke/systemic embolism. According to 
the proposed new indication, dabigatran, if granted 
ﬁ nal approval, would be marketed in the 110-mg and 
150-mg strengths. It would be indicated for the pri-
mary prevention of stroke and systemic embolism in 
adult patients with nonvalvular atrial ﬁ brillation with 
one or more risk factors -namely, previous stroke, 
transient ischemic attack, or systemic embolism; left 
ventricular ejection fraction <40%; symptomatic heart 
failure (NYHA class 2); age >75 years; and/or age >65 
years associated with one of the following: diabetes 
mellitus, coronary artery disease, or hypertension.
Conclusion 
Patients with atrial ﬁ brillation have a high risk of 
stroke and an increased risk of stroke recurrence. War-
farin is currently the standard of care for high-risk AF 
Goals for new anticoagulants 
A Blockage of tissue factor VIIa pathway (example: 
rNAPc2)
B Speciﬁ c blockers of FXa (examples: rivaroxaban, 
apixaban and edoxaban)
C Direct thrombin blockers (example: dabigatran)
RE-LY (Randomized Evaluation of Long-Term 
Anticoagulant Th erapy), evaluated 2 doses of the ac-
tive direct thrombin inhibitor dabigatran (110 and 150 
mg, twice daily) in 18,113 patients with nonvalvular 
AF. At a low dose (110 mg, twice daily) dabigatran 
was as eﬀ ective as warfarin in reducing the primary 
outcome of stroke or systemic embolism, and at a high 
dose (150 mg twice daily) it was superior to warfa-
rin. Th e primary outcome occurred at rates of 1.69% 
per year in patients receiving warfarin and 1.53 and 
1.11% per year in patients receiving dabigatran 110 
and 150 mg, respectively. Th e RRs compared with 
warfarin were 0.91 for 110 mg (95% CI = 0.74–1.11; p 
< 0.001 for noninferiority) and 0.66 for 150 mg (95% 
CI = 0.53–0.82; p < 0.001 for superiority). Th e rates of 
major bleeding were signiﬁ cantly lower for dabigatran 
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patients and in patients with AF who have had a stroke 
or TIA. However, warfarin is underutilized in patients 
with atrial ﬁ brillation, at a cost of unnecessary strokes 
and disability. Fear of bleeding accounts for some of the 
underuse, but the diﬃ  culties of warfarin use (e.g., the 
need for repeated INR monitoring and dietary restric-
tions) also play a role. New antithrombotic agents that 
can be given in ﬁ xed doses without coagulation moni-
toring oﬀ er new treatment possibilities for the preven-
tion of stroke in patients with atrial ﬁ brillation.
